Based in Pasadena, CA, Sanguine Corporation develops and markets medical products derived from chemical compounds known as perfluorocarbons (PFCs). More specifically, the company develops a PFC emulsion, Fluosol, which is the only artificial “blood substitute” approved by the FDA to date for medical purposes. Developed in part by Dr. Thomas Drees, current CEO of Sanguine, Fluosol serves as an excellent dissolving medium for oxygen. Due to difficulties with maintaining the environment in which the emulsion is stored, widespread use of the original compound was discontinued in the early nineties.
Sanguine uses a second generation adaptation of Fluosol to produce PHER O² in an attempt to circumvent the inadequacies of the original formula while maintaining its beneficial properties. Dr. Drees has always been convinced of the value of PFCs as oxygen-carrying blood supplements, and along with a team of experts in the field, has worked tirelessly to develop the product for use in transfusions, transplant organ transport, and treatment for heart attack and stroke.
In addition to its perceived medical applications, oxygen rich PHER O² may be useful in fields like personal care. At high concentrations, oxygen can kill all types of infectious cells such as bacteria, mold, and yeast. This gives rise to applications like deodorants, mouthwash, antiseptic body cleansers and more.
PHER O² has only to receive FDA approval in order for the company to take advantage of the significant licensing opportunities that are present. Frank Marra, spokesman for Sanguine asserts the pre-clinical evaluations to be progressing well, and stated: “We expect PHER-O2 to be an integral part of the Company’s future, once the 510(k) approval is complete.”
Let us hear your thoughts below: